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Abstract
RNA-Seq is increasingly being used to measure human RNA expression on a
genome-wide scale. Expression profiles can be interrogated to identify and
functionally characterize treatment-responsive genes. Ultimately, such
controlled studies promise to reveal insights into molecular mechanisms of
treatment effects, identify biomarkers, and realize personalized medicine.
RNA-Seq Reports (RSEQREP) is a new open-source cloud-enabled framework
that allows users to execute start-to-end gene-level RNA-Seq analysis on a
preconfigured RSEQREP Amazon Virtual Machine Image (AMI) hosted by
AWS or on their own Ubuntu Linux machine. The framework works with
unstranded, stranded, and paired-end sequence FASTQ files stored locally, on
Amazon Simple Storage Service (S3), or at the Sequence Read Archive (SRA).
RSEQREP automatically executes a series of customizable steps including
reference alignment, CRAM compression, reference alignment QC, data
normalization, multivariate data visualization, identification of differentially
expressed genes, heatmaps, co-expressed gene clusters, enriched pathways,
and a series of custom visualizations. The framework outputs a file collection
that includes a dynamically generated PDF report using R, knitr, and LaTeX, as
well as publication-ready table and figure files. A user-friendly configuration file
handles sample metadata entry, processing, analysis, and reporting options.
The configuration supports time series RNA-Seq experimental designs with at
least one pre- and one post-treatment sample for each subject, as well as
multiple treatment groups and specimen types. All RSEQREP analyses
components are built using open-source R code and R/Bioconductor packages
allowing for further customization. As a use case, we provide RSEQREP results
for a trivalent influenza vaccine (TIV) RNA-Seq study that collected 1 pre-TIV
and 10 post-TIV vaccination samples (days 1-10) for 5 subjects and two
specimen types (peripheral blood mononuclear cells and B-cells).
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Introduction
The advent of next-generation sequencing (NGS) technologies has dramatically reduced costs and thus democratized
sequencing1. Consequently, both big research consortia and
small laboratories now have the ability to utilize large-scale
genomic applications such as RNA sequencing (RNA-Seq) for
transcriptome profiling. However, while sequencing cost is
on the decline, the cost of data storage, analysis and interpretation is increasing1. Major challenges for analyses of
RNA-Seq data include the need for a substantial informatics
hardware and software infrastructure as well as a wide range of
computational skills to effectively manage and process the data.
With the plethora of published bioinformatics software, data
formats, and human genome information, careful bioinformatics workflow development, parameterization, reference dataset
management, and execution are required to generate consistent,
reproducible and high-quality analysis datasets2. Interpretation
of RNA-Seq data requires special statistical and visualization
techniques3,4. In addition, most of the NGS bioinformatics
software only runs on the Linux operating system (OS) or is
dependent on Linux tools/utilities. These requirements limit the
ability of small labs and individual principal investigators to analyze such data, in particular, those that use desktop computers
running non-Linux based OS with limited IT support. Emerging information technologies, bioinformatics workflow engines,
and open-source analytical modules are presenting opportunities
to reduce this burden5. Virtualization technologies, for example,
now allow entire OS replete with all the necessary software
packages to be archived and then instantiated just about anywhere
at a moment’s notice, independent of the hardware architecture
available. For instance, all software components and dependencies can be encapsulated within Virtual Machines (VMs). These
characteristics of virtual appliances allow users to choose the
number and size of VMs to be provisioned and thus provide
on-demand computational scalability. Commercial cloud service
providers such as Amazon Web Services, Google Cloud Platform,
and Windows Azure provide user-friendly web-based tools to
manage VMs and associated computational resources, including cloud storage, networking, security, identity management,
and backup and disaster recovery. This pay-as-you go model
eliminates upfront capital expenses by converting the budgeting representation of bioinformatics processing tasks and storage
into well-defined operational costs. The open-source R statistical programming language in combination with the Bioconductor
package resource provides researchers with a consistent way
to share and use specialized statistical methods for RNA-Seq
analysis6,7. In combination with the R knitr package, analysis
data sets can be processed automatically using R and summarized
in reports by integrating formatting instructions with analytical
components8. Together, these technologies can reduce analysis
time and programming effort, allow more accurate estimation
of hardware costs, improve quality of results, and facilitate
reproducible research by transparently documenting all steps
including software and OS.

RNA-Seq allows snapshot measurements of the human transcriptome by partially sequencing reverse-transcribed RNA transcripts
(cDNA) expressed in cell populations or single cells of interest.
In the context of clinical trials, the goal of transcriptomics studies
is to identify and better understand changes in cell states on the
gene expression level that can be attributed to a certain treatment (e.g., a vaccine or drug)9,10, or changes that can predict
individual treatment responses (e.g. the likelihood of developing
protective levels of antibody)11,12. The number of RNA-Seq reads
(short DNA sequence) corresponding to a transcript has been
shown to be linearly associated with true transcript abundance
spanning a large quantitative range13. Prior to gene expression
quantification, processing of human RNA-Seq data requires a computationally intensive alignment step that maps sequence reads
against the human reference transcriptome and/or genome
sequence14–16. Resulting alignment metrics including genomic
mapping locations (chromosome and position), alignment
information (insertions, deletions, and matching bases), alignment quality scores, among other information, are recorded in the
form of Binary Alignment Mapping (BAM) files17. Various algorithms have been developed that use this mapping information for
determining/counting which sequence read originated from a
certain gene, gene isoform, or gene exon18–23. Following gene
expression quantification, key analysis steps include the detection of treatment-responsive genes (e.g. 4) and subsequent
characterization of these genes using pathway enrichment
analysis (e.g. 24). Challenges prior to RNA-Seq data interpretation include (1) estimation of expected cost for storage and
data processing, (2) provisioning of computational resources
for storage and data processing, (3) installation of Linux OS,
required bioinformatics software, and reference data sets,
(4) suitable analytical methods including advanced data visualizations to summarize key tends in the data, and (5) automation and
documentation of all steps to facilitate reproducible research.
In this article, we summarize the RSEQREP framework we
developed that allows researchers to address these challenges
and to streamline the transition from a desktop environment to a
server-based scalable cloud infrastructure using Amazon Web
Services (AWS). Alternatively, the framework can be installed on
a local Ubuntu machine via installation scripts that we provide.
We exemplify the framework’s capabilities using RNA-Seq data
generated for an influenza vaccine study that extracted RNA
from peripheral blood mononuclear cells (PBMCs) and B-cells
samples collected from 5 subjects prior to trivalent influenza
vaccine (TIV) vaccination and at 10 time points post TIV vaccination (days 1-10) (GEO accession: GSE45764, Dataset 1,10).

Methods
Implementation
Figure 1 provides an overview of RSEQREP software components. The framework is organized into four main components:
(1) reference data setup, (2) pre-processing, (3) analysis, and
(4) reporting. The pre-processing component uses a combination
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Figure 1. RNA-Seq Reports (RSEQREP) implementation overview. RSEQREP provides a reproducible start-to-end analysis solution
for RNA-Seq data by automating (1) reference dataset initialization/download, (2) RNA-Seq data processing (3) RNA-Seq analysis, and
(4) reporting including a summary PDF report and publication-ready table and figure files. Steps can be run in a modular fashion and key
computational metrics are tracked in a SQLite database. The software runs on a pre-configured RSEQREP AMI or on a local Ubuntu Linux
machine. Users can customize individual steps and enter their experimental design information via an Excel configuration file.
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of open-source software, shell, R, and Perl scripts and a SQLite
relational database to process raw sequence data, quantify gene
expression, and track storage, file check-sums, CPU, memory,
and other runtime metrics. The analysis component is based on R
using both custom R programs, as well as existing R/Bioconductor
packages. The reporting component is based on R, the knitr
R package, and LaTeX for reproducible and automatic PDF
report and figure/table generation. All components read userdefined arguments from the respective tab in the RSEQREP
configuration spreadsheet (RSEQREP/config/config.xls).

Operation
All four workflow components can be run in sequence
via the RSEQREP/run-all.sh script or run individually to
update results of the respective component. When running each
individual step, the most recent version of the configuration file
will be reloaded to ensure that any modifications to the configuration will be reflected. This is particularly useful for optimizing
results and customizing result presentation, for example, by
removing outliers, optimizing the low-expression cut-off, or
adjusting the color-coding range for heatmaps. In the following, we provide an overview of each of these steps.
Additional information can be found in the method section
of the RSEQREP summary report (Supplementary File S1).
Step 1) Reference Data Set-up. The RSEQREP/setup.sh script
reads all user-specified arguments provided in the config.xls file,
downloads all required reference data including user-specified
versions of the human reference genome sequence and associated
gene model information from the Ensembl database25. Input for
pathway enrichment analysis is handled via Gene Matrix Transposed (GMT) files. For GMT files, Entrez Gene IDs, Ensembl
Gene IDs, or gene symbols are supported and will be automatically mapped to the human Ensembl reference annotations. We
recommend that users obtain reference pathway GMT files from
the Molecular Signatures Database (MSigDB)26. The MSigDB
import is not automated as download requires registration but
the location of downloaded GMT file can be specified in the
configuration file. We do provide a script (RSEQREP/source/shell/
download-gene-sets.sh) to automatically download Reactome,
Blood Transcription Module27, and KEGG pathway information
and convert this information to GMT files (note, a license may
be required prior to downloading KEGG pathway information).
Following the reference dataset download, an index of the
human reference genome sequence will be created to optimize
reference alignment searches15,16. Result files generated as part of
this step are saved under the data output directory.
Step 2) Data Pre-processing. Based on FASTQ file input
specifications in the config.xls, the RSEQREP/run-pre-processing.sh
script downloads and decrypts (optional) FASTQ files hosted on
AWS Simple Storage Service (S3) storage (https://aws.amazon.
com/s3), a local file location (Linux file path), or directly from
Sequence Read Archive (SRA)29 via FTP URLs. Following the
download, the script executes sequence data QC (FastQC), reference genome alignments (STAR16 or Hisat215 splice-aware
aligner on stranded, unstranded, or paired-end read data as
specified in the config.xls), reference based compression to generate storage-optimized CRAM files (SAMtools17), gene expression

quantification (featureCounts as implemented in subread18), and
reference genome alignment QC (RSeQC30). Additionally, the
script tracks program arguments, program return codes, input and
output file names, file sizes, MDS checksums, wall clock times,
CPU times and memory consumption in a SQLite relational database. Interim result files generated as part of this step are saved
under the specified pre-processing output directory.
Step 3) Data Analysis. The RSEQREP/run-analysis.sh script
initializes analysis datasets for the final reporting step including
(1) TMM-normalization31 and exclusion of low-expressed
genes, (2) principal component analysis (PCA), distance matrix
calculations for non-metric multidimensional scaling (MDS), and
hierarchical clustering for global multivariate analyses, (3) log2
fold change calculations used as input for heatmap and coexpressed gene-cluster analyses, (4) identification of differentially
expressed (DE) genes (edgeR32), co-expressed gene clusters
(pvclust33), and enriched pathways (GoSeq24). Interim result
files generated as part of this step are saved under the specified
report output directory.
Step 4) Automatic Report Generation. The RSEQREP/run-report.sh
script produces the final results. It runs R analyses on the intermediate analysis files generated in Step 3, generates a summary
PDF report using the knitr R package in combination with LaTeX,
and result tables in gzipped .csv format as well as individual
figure files in .pdf, and .png format. This script also summarizes
key run time statistics that were collected as part of Step 2.
Result files generated as part of this step are saved under the
specified report output directory.

Minimal system requirements
A 35 GiB Elastic Block Store (EBS) volume, i.e. storage
immediately accessible to the OS (http://docs.aws.amazon.com/
AWSEC2/latest/UserGuide/EBSVolumes.html), sufficiently covers
space for the OS, user accounts, reference data, and to process
and analyze dataset sizes similar to that of the influenza vaccine
case study when CRAM compression is deactivated. To
accommodate storage for CRAM-compressed files and studies
with larger sample sizes and/or sequence coverage, additional
EBS volumes are required (see information on AWS set-up under
RSEQREP/aws/aws-setup.docx).
We found that a c3.xlarge computational Elastic Compute Cloud
(EC2) instance type (4 vCPUs, 7.5 GiB, https://aws.amazon.com/
ec2/instance-types) is sufficient for data processing and analysis,
but a higher memory machine (c3.4xlarge: 16 Gib for HISAT2
and c3.8xlarge: 37 Gib for STAR) is required to successfully
complete the indexing of the reference genome sequence as part
of Step 1.

Installation
We provide a pre-configured RSEQREP Amazon Virtual Machine
Image available on AWS at (https://aws.amazon.com, AMI ID:
RSEQREP (RNA-Seq Reports) v1.0 (ami-e1708b9b)) that combines the Ubuntu operating system Version 16.04.2 (long-term
support) with all additional software that is required for RSEQREP
operation (RSEQREP/SOFTWARE.xlsx). We prepared a manual
that provides instructions on how to set-up an AWS instance
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including mounting of EBS volumes for local storage and an
optional Elastic IP address for machine access (RSEQREP/aws/
aws_instructions.docx). Alternatively, we provide installation
scripts that can be executed on a local Ubuntu machine
(Version 16.04.2) to install necessary dependencies (RSEQREP/
ubuntu/install-software.sh). In both cases, AWS and local set-up,
prior to workflow execution, users would need to pull the
latest RSEQREP source code from GitHub (git clone https://
github.com/emmesgit/RSEQREP).

Configuration
RSEQREP configuration is handled via the RSEQREP/config/
config.xlsx file. The first tab allows users to specify sample
metadata. Fields include subject ID, sample ID, sampling time
point, a flag (is_baseline) that indicates if a sample was collected prior to treatment, the treatment group, specimen type (e.g.
B-cells, PBMCs, etc.), and FASTQ sequence file location (AWS S3,
local, or remote SRA location). In addition, color-coding for time
points, treatment groups, and specimen types can be defined. The
second tab specifies options related to the pre-processing step. This
tab uses a two-column key value pair format to define options.
For example, to specify the Ensembl database version 74, users
can set the version value via the ensembl_version key value pair
to 74. Other options include the type of RNA-Seq data (stranded:
yes/no) and reference alignment software (Star or Hisat2).
Paired-end experiments can be accommodated for each
sample by specifying two input FASTQ files. The third tab
allows users to customize analysis and reporting components.
Options include specification of cut-offs to define lowly-expressed
genes, DE genes, and enriched pathways, as well as the distance
metric and hierarchical clustering algorithm used for heatmap
and gene clustering analysis. For further information, see descriptions and examples for each of these options in the influenza
vaccine case study configuration file (Supplementary File S2).
We implemented the framework to dynamically adjust the report
presentation depending on the number of subjects, time points,
specimen types, and treatment group combinations. For example, Venn diagrams are shown for comparisons between up to
five sets (e.g. five time points). Larger sets are accommodated
via UpSet plots34. The configuration file allows users to carry out
subgroup analysis by limiting the metadata file to samples,
treatment groups, and time points of interest.

Use Case
To illustrate the capabilities of RSEQREP, we analyzed a publicly available RNA-Seq dataset comprising 110 RNA-Seq
samples: five subjects, 11 time points (pre-vaccination and
days 1-10 post-vaccination), two specimen types (PBMCs and
B-cells), and one treatment group (Trivalent Influenza Vaccination
(TIV)) (GEO accession: GSE45764, Dataset 1,10). The unstranded
single-end RNA-Seq experiment was carried out with a read
length of 65 nt (nucleotides) and an average sequence coverage of
16 million total mapped reads. The study was designed to obtain
detailed information on the early temporal gene expression response
following TIV vaccination in both PBMC and B-cells. The configuration file that specifies the case study experimental design,
public SRA FASTQ FTP URLs, data processing and analysis

parameters is provided in Supplementary File S2. The configuration file allows users to reproduce RSEQREP results for this case
study on their own RSEQREP AWS instance or Ubuntu Linux
machine. Supplementary File S1 represents the corresponding
RSEQREP Summary PDF report, including 131 figures and 135
tables. In the following, we describe a subset of key findings
(referenced supplemental tables and figures refer to the
corresponding results in the supplemental PDF report). See
Supplementary File S1 methods for additional information on preprocessing and analysis steps.

Global gene expression patterns and DE gene time trends
PCA results revealed that most variation in gene expression based
on standardized log2 counts per million across all 110 samples
was attributable to cell type (B-cells vs. PBMCs, Figure 2). In
addition, two extreme outliers, including one B-cell sample
that was likely mislabel as a PBMC sample, were identified.
These samples were added to the configuration file as outliers
to be excluded from downstream analysis. Negative binomial
models as implemented in the edgeR package32 were fit to identify genes that were DE compared to pre-vaccination at each of
the post-vaccination days. UpSet plots visualizing the number and
overlap of DE genes over time are presented in Figure 3. PBMCs
showed overall peak DE responses at day 1 (24 hours after TIV
vaccination) with 136 genes being DE compared to pre-treatment
gene expression levels. Between days 1–4, PBMC DE signals
declined followed by a broader second peak response for
days 5–8 reaching the second highest response of 96 DE genes at
day 6. While most DE genes in PBMCs at day 1 were unique (106
of 136 genes (78%)), most DE genes at day 6 (64 of 96 (67%))
were overlapping with other DE gene responses, in particular, with
days 5, 7, and 8. In contrast to PBMCs, B-cells did not
exhibit a noticeable DE gene signal at day 1, but showed
responses between days 5–8 (121–481 genes) reaching highest responses at day 6 (481 genes). While some DE genes were
unique to day 6 (168 of 481 (35%)), many were shared with
day 7 (124 genes), as well as day 7 and day 8 (72 genes). For
both cell types, most DE genes were up-regulated from prevaccination (Figure 3, middle panel vs. right panel). Most of
the overlap between PBMC and B-cell DE genes was observed
at day 6, at which 62 of 96 DE PBMC genes (65%) were also
reported as DE in B-cells (Figure S35). Tables S7–S26 list
individual DE gene results. In the following, pathway enrichment analysis results for peak DE responses and a selection of
identified co-expressed gene clusters are summarized.
Pathway enrichment analysis results
To functionally characterize DE gene responses, pathway enrichment analysis as implemented in the GoSeq R package24 was
carried out using MSigDB (Version 5.2, Dataset 2) and Blood
Transcription Modules (Dataset 3) reference gene sets/pathways.
Pathway enrichment analysis of the day 1 peak DE gene signal
in PBMCs identified innate immune response signaling pathways
including Reactome-based interferon signaling, in particular,
interferon gamma signaling and interferon alpha/beta signaling
(Figure 4, Table S97). Top enriched GO Biological processes
included innate immune response, defense response to virus and
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response to type I interferon (Table S92). The top Blood Transcription Modules indicated that day 1 PBMC DE genes were most
preferentially enriched in monocytes (II) (M11.0) but also
enriched in activated dendritic cells (II) (M165), and enriched in
neutrophils (I) (M37.1) (Table S91). The day 6 PBMC DE gene
signal was related to plasmablast and B-cell Blood Transcription Module signatures including plasma cells, immunoglobulins
(M156.1), plasma cells, and B cells, immunoglobulins (M156.0),
and enriched in B-cells (II) (M47.1) (Table S115). The day 6
peak DE gene response in B-cells was enriched in several cell
cycle-related pathways including Reactome cellcycle mitotic,
cellcycle and DNA replication (Figure 4, Table S73). In
addition, processes involved in protein-processing such as GO
Cellular Component endoplasmic reticulum part and endoplasmic
reticulum (Table S69) and GO Biological Process protein
complex assembly and intracellular protein transport (Table S68),
as well as Reactome metabolism of proteins, post-translational
protein modification, and asparagine N-linked glycosylation were
identified (Figure 4, Table S73). Enrichment results based on
Blood Transcription Modules confirmed enrichment of cell cyclerelated modules but also identified several plasma cell-related

signatures such as plasma cells surface signature (S3), plasma
cells, and B cells, immunoglobulins (M156.0), and plasma cells,
immunoglobulins (M156.1) (Table S67). The top most enriched
MSigDB Immunological Signature was related to genes that were
up-regulated at day 7 following TIV vaccination compared
to pre-vaccination in a previous influenza vaccine study by
Nakaya et al. (GEO accession: GSE29614, 35) (Table S70).
Tables S50–S133 list all pathway enrichment analysis results.

Co-expressed gene cluster results
To identify robust clusters of co-expressed DE genes based on
correlation between log2 fold change responses, unsupervised
multi-scale bootstrap resampling as implemented in the pvclust
R package33 was executed. Several known immuno-globulin
genes had robustly correlated log2 fold changes across all postvaccination days (day 1–10) in B-cells and PBMCs reaching peak
mean log2 fold change responses between days 5 and 8 (Figure 5).
The immunoglobulin gene cluster highlighted for PBMCs
comprised 7 genes (5 immunoglobulin genes: IGHG1, IGHG3,
IGHGP, IGKC, IGKV3-11 and 2 genes not encoding for immunoglobulins: MZB1, and TNFRSF17) (Figure 5 bottom right).

Figure 2. Global gene expression pattern analysis to identify outliers and batch effects (influenza vaccine case study). RSEQREP
supports multivariate visualizations, including principal component analysis (PCA) to visualize key trends in the data. The analysis uses
standardized log2 counts per million (mapped reads) for genes that met the low expression cut off as input. As shown for the influenza
case study, the PCA analysis indicated that PBMC (highlighted in red) and B-cell (highlighted in blue) samples differ substantially in their
transcriptional profiles. In addition, two outliers were identified in relation to the other samples (highlighted in blue circles). Ellipses represent
the 95% confidence interval for the bivariate mean based on the first two principal components by specimen type.
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Figure 3. UpSet plots to summarize key differentially expressed (DE) gene time trends (influenza vaccine case study). These panels
summarize the DE gene overlap between post-treatment days for up- or down-regulated DE genes (shown to the right in black), for upregulated DE genes (shown in the middle in red), and down-regulated DE genes (shown to the right in blue), respectively within specimen
type (B-cells are shown in the top row, PBMCS in the bottom row). In each panel, the bottom left horizontal bar graph labeled SDEG Set Size
shows the total number of DE genes per post-treatment time point. The circles in each panel’s matrix represent what would be the different
Venn diagram sections (unique and overlapping DE genes). Connected circles indicate a certain intersection of DE genes between posttreatment days. The top bar graph in each panel summarizes the number of DE genes for each unique or overlapping combination. In the
top left panel, for example, the first vertical bar/column shows those DE genes that are unique to day 6 (168 DE genes). The second shows
those DE genes that are shared only between days 6 and 7 (124 DE genes). The third are those DE genes that are shared between days 6,
7, and 8 (72 DE genes), and so forth. As shown for the influenza case study, most of the DE genes for B-cells were detected and overlapped
between days 6, 7 and 8 while most of the DE genes for PBMCs were uniquely identified at day 1.
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Figure 4. Heatmaps for visualizing pathway enrichment over time (influenza vaccine case study). Reactome pathways that were
enriched in at least two conditions are shown. Cells are color-coded by enrichment score: -1 x log10(FDR-adjusted p-value). Cell values
represent the number of DE genes that overlap with a certain pathway. Numbers in brackets indicate enriched pathways, i.e. pathways that
met the specified FDR-adjusted p-value cut off. Pathways were clustered based on enrichment score. As shown for the influenza case study,
pathways related to cell-cycle as well as protein metabolism were enriched in B-cells at day 6. Both, B-cell and PBMCs showed an enrichment
of interferon signaling-related pathways at day 1.
Page 9 of 22
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Figure 5. Co-expressed gene cluster time trends (influenza vaccine case study). RSEQREP supports unsupervised multiscale bootstrap
resampling to identify co-expressed gene clusters based on their log2 fold change pattern over time. A subset of trends is shown for the
influenza case study. Several co-expressed immunoglobulin genes reached peak log2 fold changes compared to pre-treatment between day
6 and 7 while a cluster of interferon-induced antiviral (IFIT) genes showed an earlier peak in log2 fold change at day 1 in addition to a peak
at day 8 in PBMCs.
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MZB1 is known to play a role in IgM assembly and secretion
while TNFRSF17 is known to regulate humoral immunity
including plasma cells. Several known interferon-inducible genes
co-expressed in PBMCs (IFIT1, IFIT2, and IFIT3) showed an
initial peak in log2 fold change response at day 1, which declined
to pre-vaccination levels by day 4, followed by a second higher
peak response at day 8 (Figure 5 bottom left). Time trends for all
identified gene clusters are shown in Figures S79–S86.

Discussion
There is an increasing trend towards more open and transparent
research including increasing demands for sharing of source code,
software snapshots as well as enhanced scalability to facilitate
processing of increasingly larger datasets. A plethora of opensource software for RNA-Seq data processing and analysis has
been developed4,36,37. The strength of the RSEQREP framework
is its start-to-end open-source solution that combines operating
system, bioinformatics software, reference data set-up, data
processing, analysis, advanced data visualizations, and automatic
reporting. The resulting RNA-Seq PDF reports can easily be
customized, extended, and shared.
RSEQREP supports the reproducible research paradigm via its
pre-configured AMI, open-source components, user-friendly
configuration file, and functionality to rerun analyses from
start-to-end or in parts. Using the default RSEQREP AMI, in addition to on-demand scalable computational resources, has the benefit
of integrating the operating system and all software installations
as part of analysis snapshots referenced in the report, providing
for complete transparency and full reproducibility of all components involved. In addition, the software tracks computational
runtime metrics (CPU and memory consumption), which can
be used to track and estimate computational cost. Towards that
end, we benchmarked the preprocessing step for the influenza vaccine case study data (110 samples) using increasingly powerful
but also more expensive AWS EC2 instance types: c3.xlarge
(4 vCPUs; 7.5 Gib RAM), c3.2xlarge (8 vCPUs; 15 Gib
RAM), c3.4xlarge (16 vCPUs; 30 Gib RAM), and c3.8xlarge
(32 vCPUs; 60 Gib RAM). We found that the c3.2xlarge
(8 vCPUs; 15 Gib RAM) machine marks the ideal convergence
of processing time and cost (Figure 6).
RSEQREP includes a collection of best practice analytical
tools that we identified through extensive review of the peerreviewed literature. This includes TMM-normalization to
remove systematic differences between samples31, filtering of
lowly expressed genes to improve accuracy of fold change estimates and power of DE detection, application of statistical
methods that model read count variability using a discrete negative binomial distribution and share information across genes32,
the use of moderated log2 counts per million for multivariate

analyses, and adjustment for gene length bias38 as part of pathway
enrichment analysis39. In addition, the software provides several
unique visualizations, including multivariate starplots for reference alignment QC (Figures S2), co-expressed gene cluster time
trends (Figure 5), as well as pathway enrichment heatmaps
(Figure 4) and radar plots (Figure S117).
RNA-Seq data processing and analysis is a constantly evolving
field and there is no consensus on how to best analyze the data.
For example, RSEQREP summarizes gene expression on the
gene level - a widely used robust gene expression quantification
approach18,19. However, methods that support expression quantification on the gene-isoform level have been developed20–23.
Depending on the research question, RNA-Seq analysis may
include novel transcript/splice junction discovery, determination of single nucleotide polymorphism (SNPs), detection of
RNA-editing events, and fusion genes40. In addition, several
other popular DE gene detection algorithms such as DESeq2
exist41. While such additional analysis choices are currently not
implemented in RSEQREP, the key advantages of this framework are that users have complete access to the source code to
make custom updates to all workflow, analysis, and reporting
components. In combination with scalable cloud resources this
allows for rapid prototyping of analysis reports.
Using RSEQREP on published RNA-Seq data of an influenza
vaccine study10, we confirmed key transcriptional events in
PBMCs and B-cells following TIV vaccination10. Three of five
subjects in this study had reported previous influenza vaccinations.
A memory response was confirmed by the RSEQREP analysis,
which identified an early plasma cell and cell proliferation signature in B-cells with a peak 6 days following vaccination. This
signal included cluster responses for several co-expressed immunoglobulin genes as well as an up-regulation of genes preferentially involved in protein assembly, protein transport, ER-related
pathways – all of which are at the core of antibody-generating cellular machinery. While not as strong as for B-cells, a peak day 6
plasma cell signature and co-expressed immunoglobulin gene
response was also identified in PBMCs. This makes sense as
B-cells are included in bulk PBMCs. PBMCs showed a strong
up-regulation of an innate immune signaling responses 24 hours
post-vaccination, in particular, responses related to interferon
signaling. This signaling response was enriched in monocyte,
dendritic cell, and neutrophil-specific gene expression signatures indicating that it was driven by the innate immune cell
subset within PBMCs. Several co-expressed genes in the IFIT
gene family were significantly up-regulated at day 1. These
genes are known to be activated following interferon signaling and to exhibit antiviral activity by recognizing and
inhibiting viral RNA42,43. This is in agreement with other studies
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Figure 6. Wall clock time benchmarks for RNA-Seq pre-processing steps by AWS EC2 instance type. Metrics are based on 110 influenza
case study RNA-Seq samples. The following instance types were used: c3.xlarge (4 vCPUs, 7.5 GiB Mem), c3.2xlarge (8 vCPUs, 15 GiB
Mem), c3.4xlarge (16 vCPUs, 30 GiB Mem), c3.8xlarge (32 vCPUs, 60 GiB Mem). Median wall clock time is summarized as tracked in the
RSEQREP SQLite database. The biggest relative reduction in wall clock time across processes was observed when switching from the 4
vCPU to the 8 vCPU instance type (c3.xlarge vs. c3.2xlarge). Higher core machines (16 and 32 vCPUs) did result in further reduced wall clock
time for completing reference alignments (HISAT2) and gene expression quantification (Subread) but the change was not as substantial.

that have shown that IFIT genes are up-regulated 24 hours postinfluenza vaccination12,44.

Data and software availability
RSEQREP source code available from: https://github.com/
emmesgit/RSEQREP
Archived source code as at time of publication: DOI is http://doi.
org/10.5281/zenodo.106911445

RSEQREP Amazon Virtual Machine Image available from:
https://aws.amazon.com, AMI ID: RSEQREP (RNA- Seq Reports)
v1.0 (ami-e1708b9b))
License: Subject to various licenses, namely, the GNU General Public License version 3 (or later), the GNU Affero General
Public License version 3 (or later), and the LaTeX Project
Public License v.1.3(c).
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A list of the software contained in this program, including
the applicable licenses, can be accessed at https://github.com/
emmesgit/RSEQREP/SOFTWARE.xlsx
Dataset 1. RNA-Seq of PBMC and B cell gene expression
profiles in healthy humans following influenza vaccination
available from NCBI GEO with accession number GSE45764.
Dataset 2. MSigDB Version 5.2 GMT gene set files used for the
influenza vaccine case study available from:
http://software.broadinstitute.org/gsea/msigdb/download_
file.jsp?filePath=/resources/msigdb/5.2/msigdb_v5.2_files_to_
download_locally.zip
For MSigDB license terms, please refer to http://software.broadinstitute.org/gsea/license_terms_list.jsp. Users are requested to
create a login prior to data access:
http://software.broadinstitute.org/gsea/register.jsp?next=index.jsp

Dataset 3. Blood Transcription Modules GMT file used for
the influenza vaccine case study available from:
https://www.nature.com/articles/ni.2789#supplementary-information
(Zip file 1).
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doi:10.5256/f1000research.14148.r29277
Ben Busby
National Center for Biotechnology Information, National Library of Medicine, National Institutes of
Health (NIH), Bethesda, MD, USA
This work is an important example of building and advertising easy-to-implement yet powerful
bioinformatics pipelines with established, popular algorithms.
That said, in my opinion, three minor additions would make this manuscript much more robust, and
therefore, acceptable for publications.
First, the authors state that these pipelines should work on a variety of cloud architectures, but all they
explicitly provide is an AMI for AWS use. Containerization through Docker (not an endorsement) or some
other containerization protocol should simply bridge this gap.
Second, there are many mentions of bioconductor, but it is not clear from the manuscript whether this
particular pipeline is available in bioconductor. Please clarify.
Third, given that the components of such pipelines are continuously evolving, there should be some
documentation, either in the manuscript or the github repo about switching in new modules for mapping,
differential expression, or visualization.

Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Partly
Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Partly
Is sufficient information provided to allow interpretation of the expected output datasets and
any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the findings
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Are the conclusions about the tool and its performance adequately supported by the findings
presented in the article?
Yes
Competing Interests: An early draft version of a similar pipeline was worked on by some of the authors
at a hackathon that I ran at the New York Genome Center.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 30 Mar 2018

Johannes Goll, The Emmes Coporation, USA
We thank Ben Busby for his insightful comments and suggestions to increase the usefulness of this
software. In the following, we address each of the reviewer's comments highlighted in bold:
First, the authors state that these pipelines should work on a variety of cloud
architectures, but all they explicitly provide is an AMI for AWS use. Containerization
through Docker (not an endorsement) or some other containerization protocol should
simply bridge this gap.
To increase the software's portability, we created a public RSEQREP Docker container that
contains all the required 3rd party software. The container image is available at
https://hub.docker.com/r/emmesdock/rseqrep and can be accessed via the Docker utility using
“docker pull emmesdock/rseqrep”.
Second, there are many mentions of bioconductor, but it is not clear from the manuscript
whether this particular pipeline is available in bioconductor. Please clarify.
RSEQREP is not available as a Bioconductor R package and includes components not written in
R. The source code is available at https://github.com/emmesgit/RSEQREP
1. Third, given that the components of such pipelines are continuously evolving, there
should be some documentation, either in the manuscript or the github repo about
switching in new modules for mapping, differential expression, or visualization.
We agree that RNA-Seq data processing and analysis is a constantly evolving field and there is no
consensus on how to best analyze the data. RSEQREP includes a collection of best practice
analytical tools that we identified through extensive review of the peer-reviewed literature. Users
have complete access to the RSEQREP source code to make custom updates to all workflow,
analysis, and reporting components. In combination with scalable cloud resources this allows for
rapid prototyping of analysis reports.
Below are key RSEQREP programs to alter mapping, differential expression, visualizations, or
tables:
1) Read mapping is executed via “RSEQREP\source\perl\preprocess-rnaseq.pl”
2) DE gene analysis is executed via
“RSEQREP/source/r/02-sdeg-identification/init-edgeR-glm-model.r”
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“RSEQREP/source/r/02-sdeg-identification/init-edgeR-glm-model.r”
3) Integration of visualizations (R graphics) as part of the report is handled via
“/RSEQREP/source/knitr/*figures.Rnw” files.
4) Integration of tables (R xtable) as part of the report is handled via
“/RSEQREP/source/knitr/*tables.Rnw” files.
Competing Interests: No competing interests were disclosed.

Referee Report 19 January 2018

doi:10.5256/f1000research.14148.r29275
Anup Mahurkar
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
RSEQREP is a comprehensive RNAseq analysis pipeline for processing bulk human RNAseq data. The
pipeline bundles a number of commonly used RNAseq analysis tools to create a single pipeline for
end-to-end RNAseq data analysis. The pipeline includes tools such fastqc for data QC, STAR and Hisat
for alignment, RSeQC for generating alignment stats, edgeR for differential gene expression, a number of
R packages for clustering analysis, and GOSeq for gene set enrichment analysis. The output from all of
these tools is then used to generate a comprehensive report that summarizes the data analysis. The
pipeline can be downloaded locally and run in an Ubuntu VM or can be executed on Amazon using a
prebuilt Amazon Machine Image (AMI).
The article is well written with an example dataset used to illustrate the different outputs generated by the
pipeline. This is a useful tool that will help small labs with limited bioinformatics expertise or computational
resources run RNAseq analyses. The authors also provide documentation on the github repository. The
configuration of the pipeline is made easy through an Excel template provided in the repository.
While there are other similar tools and pipelines this is one of the few that bundles everything into a single
pipeline and could be a great tool for biologist and bioinformaticians. Following are some suggestions that
might improve the tool:
1. The authors have provided a number of useful visualizations including Heatmaps, UpSet plots,
radar plots, and PCA plots, some commonly used plots in RNAseq analysis such as MA plots, or
Volcano plots are not present. The authors could consider adding these plots to the package.
2. The generated report includes summary figures for the different analyses and tables with the list of
genes and pathways detected through the analyses. For a large analysis like the time-series
analysis used as an example the generated report includes over 300 pages. This makes it hard to
navigate through the report and find things quickly. Also, it is hard to explore the DE results by
changing log-fold cutoffs, or FDR cutoffs which could easily be done in a spreadsheet but not in a
PDF. The authors might want to consider splitting the report in two parts, a PDF report with images
and summary data and methods, and an accompanying workbook with the tables so users can
explore the results.
3. The tool requires users to build the indexes for the database used as the reference genome. This
typically requires a higher memory machine (16 GB for Hisat2, and 37 GB for STAR). The
processing itself can be done with less memory. This could pose a problem for users trying to run
this tool on a typical laptop or workstation. The authors could consider prebuilding some commonly
used indices for human, mouse, and rat genomes so all users do not have to re-index. These
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used indices for human, mouse, and rat genomes so all users do not have to re-index. These
references are relatively stable so the index may only need to be rebuilt once or twice a year. This
will ease the burden significantly for end users.
4. The authors have benchmarked their tool on Amazon to identify the most optimal instance type
(Figure 6) so users can minimize costs. The biggest performance gains seem to be when the
machine instance is changed from 4 vCPUs to 8 vCPUs. However, if a user were to want to use
STAR this instance type does not have sufficient RAM. To optimize, the user will need to either use
a larger instance for the entire processing, or launch two instances, a larger instance for the
indexing step, and a smaller instance for processing, and copy the indices. For this reason, having
pre-built indices might alleviate this issue.
5. The documentation needs some improvement, particularly if the intended audience is users with
limited computational experience. When I tried to launch the AMI on Amazon I was not sure what
username to use to log into the running instance. Through trial and error, I figured out that the
username was “ubuntu”. But it would be better if this were included in the documentation on the
github repo.
6. Another related issue is that because the pipeline reads Excel config files the user needs to create
the config file on the local machine and upload to the AMI. Most non-tech savvy users will not
necessarily know how to do it easily. The documentation could point to some utilities that could be
used to upload the edited file such as sftp.
7. It appears that the system is only setup for human genome analysis. While editing the config file it
was not clear where to specify the reference genome information for other organisms. There is no
reason the pipeline could not work for other model organisms which are commonly used for basic
research studies. This will increase its adaption and userbase.
8. Once I had the AMI running I had a difficult time executing the test pipeline. I was getting errors
about missing directories or data files. I would recommend that the authors test the AMI and have
clearer instructions on how to download datasets and run the tools in the AMI. For instance after
cloning the github repo I tried running the setup script with the command “sh RSEQREP/setup.sh”
while I was in “/home/ubuntu” and got the following error:
“Fatal error: cannot open file '/home/ubuntu/source/r/parse-rnaseq-configuration.r': No such file or
directory”.
I then tried moving to the RSEQREP directory to run the same command and got the error:
“File does not exist! /home/ubuntu/msigdb/c2.cp.kegg.v5.2.entrez.gmt.”
Based on the error message it appears that the software expects the databases to be uploaded before
the setup script can be run but the documentation does not specify that. As a result, I was not able to test
the VM end-to-end, but with improved testing and documentation this should be easy to address.
Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets and
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Is sufficient information provided to allow interpretation of the expected output datasets and
any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the findings
presented in the article?
Yes
Competing Interests: No competing interests were disclosed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 30 Mar 2018

Johannes Goll, The Emmes Coporation, USA
We thank Anup Mahurkar for his insightful comments and suggestions to increase the usefulness
of this software. In the following, we address each of the reviewer's comments highlighted in bold:
The authors have provided a number of useful visualizations including Heatmaps, UpSet
plots, radar plots, and PCA plots, some commonly used plots in RNAseq analysis such as
MA plots, or Volcano plots are not present. The authors could consider adding these plots
to the package.
The Volcano and MA plots can be found on page Figures 20-23 in the case study report
(Supplementary File S1).
The generated report includes summary figures for the different analyses and tables with
the list of genes and pathways detected through the analyses. For a large analysis like the
time-series analysis used as an example the generated report includes over 300 pages.
This makes it hard to navigate through the report and find things quickly. Also, it is hard
to explore the DE results by changing log-fold cutoffs, or FDR cutoffs which could easily
be done in a spreadsheet but not in a PDF. The authors might want to consider splitting
the report in two parts, a PDF report with images and summary data and methods, and an
accompanying workbook with the tables so users can explore the results.
We recommend that users navigate to the figure and table listings at the beginning of the PDF
report to find content of interest or use the PDF search option. RSEQREP provides user-friendly
configuration options via a spreadsheet (see for example Supplementary File S2) including FDR
and fold change cut offs that can be adjusted prior to generating reports. In addition to the PDF
report, RSEQREP outputs all tables including DE gene lists in comma-separated values (CSV)
format which then can be used within Excel or other spreadsheet software to dynamically filter DE
gene lists.
The tool requires users to build the indexes for the database used as the reference
genome. This typically requires a higher memory machine (16 GB for Hisat2, and 37 GB
for STAR). The processing itself can be done with less memory. This could pose a
problem for users trying to run this tool on a typical laptop or workstation. The authors
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problem for users trying to run this tool on a typical laptop or workstation. The authors
could consider prebuilding some commonly used indices for human, mouse, and rat
genomes so all users do not have to re-index. These references are relatively stable so
the index may only need to be rebuilt once or twice a year. This will ease the burden
significantly for end users.
We agree that a pre-built index would be more computational effective. However, we consider
generating the index a part of the start-to-end analysis and, as a critical step to support
reproducible research, indexing software, genome, and genome annotation versions are fully
captured. This approach provides also the most flexibility to the users who can specify any
Ensembl version including associated annotations and reference genome assembly during the
initialization phase (see for example Supplementary File S2). A process to manually maintain
genome indices would quickly become out of date.
The authors have benchmarked their tool on Amazon to identify the most optimal instance
type (Figure 6) so users can minimize costs. The biggest performance gains seem to be
when the machine instance is changed from 4 vCPUs to 8 vCPUs. However, if a user were
to want to use STAR this instance type does not have sufficient RAM. To optimize, the
user will need to either use a larger instance for the entire processing, or launch two
instances, a larger instance for the indexing step, and a smaller instance for processing,
and copy the indices. For this reason, having pre-built indices might alleviate this issue.
Since we completed our computational benchmarks, newer AWS EC2 instance types have
become available. Most notably the r4.X and x1e.X instance types, which are more than capable of
providing enough memory for indexing with 4 or 8 vCPUs.
The documentation needs some improvement, particularly if the intended audience is
users with limited computational experience. When I tried to launch the AMI on Amazon I
was not sure what username to use to log into the running instance. Through trial and
error, I figured out that the username was “ubuntu”. But it would be better if this were
included in the documentation on the github repo.
We have updated our README file on GitHub (https://github.com/emmesgit/RSEQREP). We
added detailed information about the AMI, installation, execution, and troubleshooting. This
includes details on which user name and password to use to login into the AMI.
Another related issue is that because the pipeline reads Excel config files the user needs
to create the config file on the local machine and upload to the AMI. Most non-tech savvy
users will not necessarily know how to do it easily. The documentation could point to
some utilities that could be used to upload the edited file such as sftp.
We provide the Amazon AMI preconfigured with the X2GO remote Desktop software. This allows
users to connect to the instance using a user-friendly desktop environment. We have updated our
README file on GitHub (https://github.com/emmesgit/RSEQREP) to include information about
this. Additionally, the instance comes pre-configured with the Libre Office software which contains
an Excel editor.
It appears that the system is only setup for human genome analysis. While editing the
config file it was not clear where to specify the reference genome information for other
organisms. There is no reason the pipeline could not work for other model organisms
Page 20 of 22

F1000Research 2017, 6:2162 Last updated: 20 AUG 2018

organisms. There is no reason the pipeline could not work for other model organisms
which are commonly used for basic research studies. This will increase its adaption and
userbase.
We purposefully designed the software to support human clinical research studies. While at this
time, it supports only RNA-Seq analysis of human clinical samples, we may add support to expand
on this in the future. We do encourage users to modify the existing source code for their own
purposes including adaptations to support RNA-Seq analyses for other model organisms.
Once I had the AMI running I had a difficult time executing the test pipeline. I was getting
errors about missing directories or data files. I would recommend that the authors test the
AMI and have clearer instructions on how to download datasets and run the tools in the
AMI. For instance after cloning the github repo I tried running the setup script with the
command “sh RSEQREP/setup.sh” while I was in “/home/ubuntu” and got the following
error:“Fatal error: cannot open file '/home/ubuntu/source/r/parse-rnaseq-configuration.r':
No such file or directory”.
I then tried moving to the RSEQREP directory to run the same command and got the error:
“File does not exist! /home/ubuntu/msigdb/c2.cp.kegg.v5.2.entrez.gmt.”
Based on the error message it appears that the software expects the databases to be
uploaded before the setup script can be run but the documentation does not specify that.
As a result, I was not able to test the VM end-to-end, but with improved testing and
documentation this should be easy to address.
We have updated our README file on GitHub (https://github.com/emmesgit/RSEQREP). We
added detailed information about using the AMI, installation, execution, and troubleshooting. We
also updated the run-* scripts to be executed anywhere on the file system. Prior to running
RSEQREP, most suitable gene set datasets (GTM files) for the pathway enrichment analysis (e.g.
Reactome pathways, KEGG pathways, MSigDB pathways, etc.) need to be identified and
downloaded by the user and added to the RSEQREP configuration file. To make it easier for users,
we provide programs to download certain gene sets files (see our README file on GitHub page for
further documentation).
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